Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients
✍ Scribed by On behalf of the Multi-institutional Retrospective Spanish Study on the use of rituximab in refractory ITP; Francisco Javier Peñalver; Victor Jiménez-Yuste; Manuel Almagro; Alberto Alvarez-Larrán; Lluis Rodríguez; Marisol Casado; Laura Gallur; Pilar Giraldo; Roberto Hernández; Dolores Menor; Maria José Rodríguez; Dolores Caballero; Raúl González; José Mayans; Isabel Millán; José Rafael Cabrera
- Publisher
- Springer
- Year
- 2006
- Tongue
- English
- Weight
- 125 KB
- Volume
- 85
- Category
- Article
- ISSN
- 0939-5555
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Immune thrombocytopenlc purpura (ITP) and thrombotic thrombocytopenlc purpura (lTP) have each been associated with HIV Infection. Sequential occurrence of these two dlseases with a disease-free interval has been occasionally reported In the literature, whereas simultaneous manifestations of these tw